| 1 |
Malkan UY, Haznedaroglu IC, Gu Y. Antineoplastic Effects of Ankaferd Hemostat. BioMed Research International 2022;2022:1-11. [DOI: 10.1155/2022/2665903] [Reference Citation Analysis]
|
| 2 |
Beyazit F, Beyazit Y, Tanoglu A, Haznedaroglu IC. Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content. Med Hypotheses 2020;143:110150. [PMID: 32763660 DOI: 10.1016/j.mehy.2020.110150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Turk S, Malkan UY, Ghasemi M, Hocaoglu H, Mutlu D, Gunes G, Aksu S, Haznedaroglu IC. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines. SAGE Open Med 2017;5:2050312116689519. [PMID: 28293423 DOI: 10.1177/2050312116689519] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 4 |
Ardıçoğlu Y, Akar N, Haznedaroğlu İ. Endothelial Cells, Ankaferd Hemostat, and Estradiol. Turk J Haematol 2016;33:261-2. [PMID: 26376760 DOI: 10.4274/tjh.2015.0143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 5 |
Mumcuoglu M, Akin DF, Ezer U, Akar N. Ankaferd Blood Stopper induces apoptosis and regulates PAR1 and EPCR expression in human leukemia cells. Egyptian Journal of Medical Human Genetics 2015;16:19-27. [DOI: 10.1016/j.ejmhg.2014.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 6 |
Behçet AL, Kılıç H, Zengin S, Güler M, Taysi S, Yıldırım C, Sarı İ. Efficiency of Ankaferd Blood Stopper used in bleeding control on intraabdominal adhesions formed postoperatively. Clin Appl Thromb Hemost 2014;20:524-9. [PMID: 23288869 DOI: 10.1177/1076029612471710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 7 |
Koçak E, Akbal E, Taş A, Köklü S, Karaca G, Can M, Kösem B, Üstün H. Anti-inflammatory efficiency of Ankaferd blood stopper in experimental distal colitis model. Saudi J Gastroenterol 2013;19:126-30. [PMID: 23680710 DOI: 10.4103/1319-3767.111955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Uz B, Guven GS, Isik A, Kuyumcu ME, Bektas O, Eliacik E, Aksu S, Goker H, Buyukasik Y, Sayinalp N, Haznedaroglu IC. Long-term sustained hemorrhage due to bone marrow biopsy successfully treated with topical ankaferd hemostat in a bleeding-prone patient with secondary amyloidosis. Clin Appl Thromb Hemost 2013;19:338-40. [PMID: 22914810 DOI: 10.1177/1076029612457709] [Reference Citation Analysis]
|
| 9 |
Ozel-Demiralp D, Igci N, Ayhan B, Egin Y, Haznedaroglu IC, Akar N. Prohemostatic and antithrombin activities of Ankaferd hemostat are linked to fibrinogen gamma chain and prothrombin by functional proteomic analyses. Clin Appl Thromb Hemost 2012;18:604-10. [PMID: 22327821 DOI: 10.1177/1076029612436672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 10 |
Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol 2012;83:21-34. [PMID: 22079213 DOI: 10.1016/j.critrevonc.2011.10.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 11 |
Beyazit Y, Kekilli M, Haznedaroglu IC, Kayacetin E, Basaranoglu M. Ankaferd hemostat in the management of gastrointestinal hemorrhages. World J Gastroenterol 2011; 17(35): 3962-3970 [PMID: 22046083 DOI: 10.3748/wjg.v17.i35.3962] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 12 |
Taş A, Köklü S, Beyazit Y, Karaca G, Astarcı HM, Akbal E, Koçak E, Topçu G, Haznedaroglu IC. Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model. Clin Res Hepatol Gastroenterol 2011;35:549-53. [PMID: 21489900 DOI: 10.1016/j.clinre.2011.02.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
